These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7192191)

  • 1. Nomenclature of GM2-gangliosidoses.
    Nørby S
    Clin Genet; 1980 May; 17(5):320-2. PubMed ID: 7192191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset hexosaminidase A and hexosaminidase A and B deficiency: family study and review.
    Adams C; Green S
    Dev Med Child Neurol; 1986 Apr; 28(2):236-43. PubMed ID: 2940136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
    Tsuji D
    Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
    Gort L; de Olano N; Macías-Vidal J; Coll MA;
    Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Segregation of Tay-Sachs and Sandhoff alleles in a non-Jewish family.
    Lane AB; Young E; Jenkins T
    Am J Hum Genet; 1980 Nov; 32(6):920-6. PubMed ID: 7446530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
    Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic findings and current developments in sphingolipidoses.
    Pilz H; Heipertz R; Seidel D
    Hum Genet; 1979 Mar; 47(2):113-34. PubMed ID: 108196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biochemical basis of gangliosidoses.
    Sandhoff K; Conzelmann E
    Neuropediatrics; 1984 Sep; 15 Suppl():85-92. PubMed ID: 6242704
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
    Kolter T; Sandhoff K
    J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci.
    Cordeiro P; Hechtman P; Kaplan F
    Genet Med; 2000; 2(6):319-27. PubMed ID: 11339652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
    Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
    Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses.
    Kissell J; Rochmann C; Minini P; Eichler F; Stephen CD; Lau H; Toro C; Johnston JM; Krupnick R; Hamed A; Cox GF
    Mol Genet Metab; 2024 Jul; 142(3):108512. PubMed ID: 38870773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in molecular genetics of GM2 gangliosidosis].
    Wakamatsu N
    Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity of the hexosaminidase deficiency diseases.
    Johnson WG
    Res Publ Assoc Res Nerv Ment Dis; 1983; 60():215-37. PubMed ID: 6337393
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of the genetic heterogeneity of gangliosidoses in humans].
    Akhunov VS; Aronovich EL; Krasnopol'skaia KD; Mirenburg TV
    Genetika; 1989 Oct; 25(10):1861-71. PubMed ID: 2533574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
    Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
    Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suggestions for a nomenclature for the GM2 gangliosidoses making certain (possibly unwarrantable) assumptions.
    O'Brien JS
    Am J Hum Genet; 1978 Nov; 30(6):672-5. PubMed ID: 747190
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical consequences of mutations causing the GM2 gangliosidoses.
    Mahuran DJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
    Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic deficiencies of beta-N-acetylhexosaminidase A and B: Tay-Sachs and Sandhoff diseases (GM2-gangliosidosis)].
    Suzuki K
    Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):721-7. PubMed ID: 2978703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.